A Barclays strategist report raises alarms about the potential impact of weight loss drugs like Ozempic on the fast food industry, suggesting a shift in consumer behavior that could threaten giants like McDonald's and Pepsi. The discussion highlights how these drugs may also affect alcohol and tobacco consumption, leading to decreased demand for companies like Altria. Additionally, the report calls for credit protection against healthcare firms that profit from weight-related health issues, indicating a broader market disruption.
